指南与共识血脂与心血管预防冠心病心力衰竭与心肌病

抑郁症与心血管疾病:指南中的认知缺口

Depression and cardiovascular disease: mind the gap in the guidelines.
指南 / 共识 · Eur Heart J · 2025-01-01

该研究系统检索2013至2024年发布的65部心血管临床实践指南,评估其对抑郁症的覆盖程度。

要点

  • 仅23%的心血管指南同时提供抑郁筛查与治疗建议。
  • 认知行为疗法和SSRI为最常推荐的干预,但药物相互作用关注不足。
  • 卒中指南贡献了68%的抑郁相关推荐,心脏康复指南占24%。

核心结论

  • 心血管指南对抑郁症的筛查与治疗指导存在显著缺口,需系统纳入心理健康专家参与制定。

研究设计与样本

  • 系统检索2013至2024年发表的英文心血管临床实践指南,共纳入65部,覆盖一般心血管病、心衰、冠心病、外周动脉疾病、卒中和主动脉疾病。

主要发现

  • 仅23%的指南同时提供抑郁筛查和治疗建议,12%有心理健康专业人员参与制定。
  • 卒中指南提供68%的抑郁相关推荐,心脏或卒中康复指南提供24%,女性特异性指南无治疗推荐。
  • 认知行为疗法是最常推荐的心理治疗(29%指南),选择性5-羟色胺再摄取抑制剂是最常推荐的药物(20%指南),仅3%指南涉及抑郁治疗相关的药物-疾病相互作用。

临床怎么用

  • 心血管医生应主动筛查抑郁,尤其在心衰、冠心病和卒中患者中,并参考现有指南推荐启动心理或药物治疗。
  • 关注抗抑郁药与心血管药物的相互作用,目前指南对此覆盖不足,需个体化评估。
  • 在心脏康复和卒中康复中整合抑郁管理,可提高患者生活质量和预后。

局限性

  • 仅纳入英文发表的指南,可能遗漏非英语地区指南。
  • 未评估指南推荐的具体实施障碍或患者层面结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with cardiovascular disease (CVD) experience higher rates of depression compared to the general population, complicating disease management, medication adherence, and lifestyle changes. Co-occurring CVD and depression are associated with reduced quality of life, poorer outcomes, and increased mortality. This study aimed to evaluate how CVD clinical practice guidelines (CPGs) address depression, including practical management guidance. A systematic search (2013-2024) identified 65 CPGs published in English, covering general CVD, heart failure, coronary artery disease, peripheral artery disease, stroke, and aortic disease. Seventy-one percent acknowledged depression as a risk factor and 12% referred to a dedicated CPG for comprehensive guidance. Yet only 23% of CPGs provided both screening and treatment recommendations for its management. Twelve percent involved mental health professionals in their development, while 24% focussed on cardiac or stroke rehabilitation, and 9% on women. Stroke CPGs delivered the majority of recommendations (68%), likely due to neurologists' involvement. Cardiac and stroke rehabilitation CPGs delivered 24% of recommendations, whereas women-specific CPGs offered no treatment recommendations. While cognitive-behavioural therapy was the most recommended psychotherapeutic intervention (29% of CPGs), and selective serotonin reuptake inhibitors were the pharmacotherapy most recommended (20% of CPGs), only 3% of CPGs addressed drug-disease interactions associated with treating depression. Depression negatively impacts patients' lives, irrespective of CVD outcomes. CVD CPGs should systematically address depression, consistently involving mental health specialists, to deliver screening and treatment guidance tailored to distinct patient populations for holistic patient care.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Blatch Armon D, Buhayer A, Miteva K, et al. Depression and cardiovascular disease: mind the gap in the guidelines. Eur Heart J. 2025. PMID: 40878995. doi:10.1093/eurheartj/ehaf479

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。